Semax, Selank, and NAD+ attract interest, but sleep, cardiovascular health, activity, hearing, and evaluation of new symptoms deserve priority.
Staging approval
Review this article
Use this staging form to record Dr. Mueller’s decision for “Brain-Health Peptides Versus the Foundations With Stronger Evidence.”
Do not let a wellness label delay evaluation
New confusion, sudden neurologic symptoms, severe headache, weakness, speech difficulty, or acute change requires urgent assessment. Gradual brain fog or memory change still deserves a clinician conversation when it is persistent, worsening, or affecting daily life.
Sleep apnea, depression, anxiety, thyroid disorders, anemia, medication effects, substance use, hearing loss, metabolic health, and many other factors can influence cognition.
Why emerging peptides remain uncertain
Semax and Selank are discussed online for focus, mood, or cognition, but popularity is not a substitute for large, well-controlled human trials using the same product and route being marketed. FDA safety summaries describe limited information and potential immunogenicity concerns for compounded versions.
NAD+ and its precursors are biologically relevant and actively studied. Current evidence does not establish that a specific NAD+ protocol prevents dementia or reverses cognitive aging.
Build the higher-confidence brain-health plan first
Manage blood pressure, diabetes, cholesterol, tobacco exposure, sleep, hearing, physical inactivity, depression, and social isolation. Maintain regular movement, cognitively engaging activities, and appropriate preventive care.
An experimental option should never replace these foundations or a diagnostic workup. If discussed, it should come with a clear explanation of the evidence gap, product quality, safety uncertainty, and how benefit would be measured.